Orforglipron + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Urinary Incontinence,Stress
Conditions
Urinary Incontinence,Stress
Trial Timeline
Sep 30, 2025 → Mar 1, 2028
NCT ID
NCT07202884About Orforglipron + Placebo
Orforglipron + Placebo is a phase 3 stage product being developed by Eli Lilly for Urinary Incontinence,Stress. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07202884. Target conditions include Urinary Incontinence,Stress.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07241390 | Phase 3 | Recruiting |
| NCT07223593 | Phase 3 | Recruiting |
| NCT07202884 | Phase 3 | Recruiting |
| NCT07153471 | Phase 3 | Recruiting |
| NCT06972472 | Phase 3 | Recruiting |
| NCT06972459 | Phase 3 | Recruiting |
| NCT06993792 | Phase 3 | Recruiting |
| NCT06952530 | Phase 3 | Recruiting |
| NCT06948435 | Phase 3 | Recruiting |
| NCT06948422 | Phase 3 | Recruiting |
| NCT06824051 | Phase 1 | Completed |
| NCT06672939 | Phase 3 | Recruiting |
| NCT06672549 | Phase 3 | Recruiting |
| NCT06649045 | Phase 3 | Active |
| NCT06584916 | Phase 3 | Completed |
| NCT06109311 | Phase 3 | Completed |
| NCT05971940 | Phase 3 | Completed |
| NCT05931380 | Phase 3 | Completed |
| NCT05869903 | Phase 3 | Active |
| NCT05872620 | Phase 3 | Completed |
Competing Products
20 competing products in Urinary Incontinence,Stress